ATLAS-OLE: AN OPEN-LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF FITUSIRAN IN PATIENTS WITH HEMOPHILIA A OR B, WITH OR WITHOUT INHIBITORY ANTIBODIES TO FACTOR VIII OR IX
- Registry ID
- LTE15174
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- GENZYME CORPORATION
- Start date
- 2022-05-17
- Last update
- 2019-11-27
Conditions
Related clinical trials
- AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF MARSTACIMAB PROPHYLAXIS IN SEVERE (COAGULATION FACTOR ACTIVITY <1%) HEMOPHILIA A PARTICIPANTS WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY <=2%) WITH OR WITHOUT INHIBITORS
- A PHASE IIIB, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS EMICIZUMAB IN PATIENTS FROM BIRTH TO 12 MONTHS OF AGE WITH HEMOPHILIA A WITHOUT INHIBITORS
- A MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB IN PATIENTS WITH MILD OR MODERATE HEMOPHILIA A WITHOUT FVIII INHIBITORS.
- ATLAS-PEDS: AN OPEN-LABEL, MULTINATIONAL STUDY OF FITUSIRAN PROPHYLAXIS IN MALE PEDIATRIC SUBJECTS AGED 1 TO LESS THAN 12 YEARS WITH HEMOPHILIA A OR B.
View on source registry